The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer
出版年份 2021 全文链接
标题
The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer
作者
关键词
-
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 22, Issue 12, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-11-06
DOI
10.1007/s11864-021-00913-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
- (2021) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
- (2021) Thierry Andre et al. LANCET ONCOLOGY
- BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
- (2020) Gary Middleton et al. CLINICAL CANCER RESEARCH
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
- (2020) R. Corcoran et al. ANNALS OF ONCOLOGY
- Host–microbiota maladaptation in colorectal cancer
- (2020) Alina Janney et al. NATURE
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
- (2020) Andrea Sartore-Bianchi et al. ESMO Open
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer
- (2019) Giacomo Bregni et al. JAMA Oncology
- Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
- (2019) Giulia Siravegna et al. CLINICAL CANCER RESEARCH
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
- (2019) C Santos et al. ANNALS OF ONCOLOGY
- ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
- (2019) C Luchini et al. ANNALS OF ONCOLOGY
- A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
- (2019) Robert Piskol et al. CLINICAL CANCER RESEARCH
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials.
- (2019) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- 526PDTRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study
- (2019) Y Nakamura et al. ANNALS OF ONCOLOGY
- 527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
- (2019) J H Strickler et al. ANNALS OF ONCOLOGY
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- RET fusions in solid tumors
- (2019) Andrew Y. Li et al. CANCER TREATMENT REVIEWS
- RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
- (2018) F Pietrantonio et al. ANNALS OF ONCOLOGY
- O-021Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability–high (MSI-H) colorectal cancer: KEYNOTE-164
- (2018) D Le et al. ANNALS OF ONCOLOGY
- Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
- (2018) Jeffrey S. Ross et al. CANCER
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies
- (2018) Matthew Alderdice et al. JOURNAL OF PATHOLOGY
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
- (2018) Jennifer Ma et al. Nature Communications
- LBA17Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
- (2018) G D Demetri et al. ANNALS OF ONCOLOGY
- 60PDColon cancer molecular subtype intratumoral heterogeneity and its prognostic impact: An extensive molecular analysis of the PETACC-8
- (2018) P Laurent-Puig et al. ANNALS OF ONCOLOGY
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer
- (2017) Rachel V. Purcell et al. Scientific Reports
- Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer
- (2016) Philip D. Dunne et al. CLINICAL CANCER RESEARCH
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
- (2016) David Barras et al. CLINICAL CANCER RESEARCH
- Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
- (2016) Filippo Pietrantonio et al. CLINICAL CANCER RESEARCH
- Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
- (2016) Anne Trinh et al. CLINICAL CANCER RESEARCH
- Microsatellite instability is associated with reduced disease specific survival in stage III colon cancer
- (2016) H.M. Mohan et al. EJSO
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
- (2016) Beth O. Van Emburgh et al. Nature Communications
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
- (2015) C. Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
- (2015) Emanuele Valtorta et al. MODERN PATHOLOGY
- Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
- (2015) Alexandre Calon et al. NATURE GENETICS
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
- (2014) Marta Schirripa et al. INTERNATIONAL JOURNAL OF CANCER
- RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
- (2014) Newton ACS Wong et al. JOURNAL OF CLINICAL PATHOLOGY
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
- (2013) Felipe De Sousa E Melo et al. NATURE MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
- (2012) Tomoya Yokota Anti-Cancer Agents in Medicinal Chemistry
- Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
- (2012) Cheng-Bo Han et al. CANCER INVESTIGATION
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency
- (2012) Sun Tian et al. JOURNAL OF PATHOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started